Evidence reviewed: 8 November 2026. Tuberculosis (TB) is an infectious disease caused mainly by Mycobacterium tuberculosis. It most often affects the lungs but can involve lymph nodes, brain, spine, kidneys and other organs. TB is both preventable and treatable, but accurate diagnosis, drug-susceptibility testing and completion of an effective regimen are essential. Standard drug-susceptible pulmonary TB treatment often lasts six months, while selected patients can receive four-month regimens. The World Health Organization (WHO) updated its consolidated treatment guidelines on 30 September 2026, expanding tailored six-month all-oral drug-resistant TB approaches and integrating palliative care [1–4].
What is the difference between active TB and latent TB infection?
Active TB disease means bacteria are multiplying and causing illness, with possible infectiousness when the lungs or larynx are involved. Latent TB infection—also called TB infection without active disease—means a person has an immune response to TB bacteria but no signs or symptoms of active disease. Such individuals are not contagious [2,5].
| Feature | TB infection without active disease | Active TB disease |
|---|---|---|
| Symptoms | Usually none. | May include cough, fever, weight loss, night sweats or site-specific symptoms. |
| Chest imaging | May be normal or show old healed changes. | May show findings compatible with disease; not diagnostic by itself. |
| IGRA/TST | Often positive, indicating immune sensitization. | Can also be positive; cannot distinguish active from latent disease. |
| Infectiousness | Not infectious. | Pulmonary/laryngeal TB may be infectious, especially before effective treatment. |
| Treatment | Preventive treatment after active disease is excluded. | Full multidrug regimen guided by susceptibility and clinical status. |
Never prescribe a latent-TB-only regimen without reasonably excluding active disease. Undertreating active TB with one drug can promote resistance and delay recovery [2,5].
How does TB spread?
TB spreads mainly through airborne particles generated by people with infectious pulmonary or laryngeal TB when they cough, speak or sing. Inhalation can result in infection, particularly with prolonged indoor exposure, poor ventilation and close contact. Risk depends on the infectiousness of the source, environment and susceptibility of exposed people [2,5].
TB is not typically transmitted by sharing utensils, handshakes, toilet seats or brief ordinary surface contact. Public-health interventions include early diagnosis, appropriate respiratory precautions, improved ventilation, contact investigation and timely treatment, without stigmatizing affected patients.
Recognizing pulmonary TB symptoms
- Persistent cough, sometimes with sputum, that lasts weeks.
- Blood in sputum (hemoptysis) in some cases.
- Fever, night sweats and unexplained weight loss.
- Fatigue, loss of appetite and chest discomfort.
- Occasionally shortness of breath or worsening general health.
TB symptoms may be mild or absent initially, especially in children or some immunocompromised patients. Chronic cough can also be caused by other conditions, and not everyone with active TB coughs blood. Persistent unexplained symptoms should prompt clinical evaluation and risk assessment [2].
Extrapulmonary TB: infection beyond the lungs
TB can affect lymph nodes, pleura, bones and joints, spine, genitourinary system, abdomen or central nervous system. Features depend on the affected organ: lymph-node swelling, back pain, pleural fluid, urinary changes or neurological symptoms may occur. TB meningitis can present with headache, fever, neck stiffness, confusion or cranial-nerve dysfunction and requires urgent hospitalization [2,5].
Severe breathlessness, major hemoptysis, altered consciousness or signs of meningitis are emergencies. The absence of classic respiratory symptoms does not exclude extrapulmonary TB.
Who is at increased risk?
Risk factors include close exposure to a person with infectious TB, HIV infection, certain immunosuppressive treatments, diabetes, undernutrition, crowded living conditions, previous TB infection and some occupational exposures. People starting TNF-alpha inhibitors or other significant immunosuppressants may need appropriate TB screening and preventive treatment before treatment begins [2,5].
TB burden varies significantly across regions. People who travel, migrate or work in high-incidence settings may need assessment based on actual exposure, symptoms and local policies rather than stereotypes about nationality.
How is active pulmonary TB diagnosed?
Diagnosis integrates symptoms and exposure history, chest imaging, microbiologic testing and drug-susceptibility assessment. WHO recommends using rapid molecular assays as an initial test in many settings rather than relying solely on conventional sputum smear microscopy [2,4].
| Test | What it contributes | Limitation |
|---|---|---|
| Rapid molecular test (NAAT) | Detects TB-complex genetic material; some assays detect rifampicin resistance. | Interpret alongside symptoms and specimens; resistance testing may require further confirmation. |
| Sputum AFB smear | Rapid microscopy indicating acid-fast organisms and potential infectiousness. | Less sensitive; does not identify TB specifically or reliably detect drug resistance. |
| Mycobacterial culture | Confirms viable organisms and permits phenotypic susceptibility testing. | Can take weeks because the organism grows slowly. |
| Drug-susceptibility testing | Identifies resistance, guides regimen and prevents ineffective treatment. | May require molecular and/or culture methods. |
| Chest X-ray | Supports evaluation of active pulmonary disease and alternative causes. | Not diagnostic alone. |
| IGRA or tuberculin skin test | Shows immune sensitization to TB antigens. | Cannot by itself distinguish active from inactive infection. |
If sputum cannot be obtained, clinicians may collect induced sputum or other specimens. Children and extrapulmonary disease may require site-specific sampling. A negative smear does not rule out active TB, especially in people living with HIV or with low bacterial burden.
What is drug-susceptible versus drug-resistant TB?
Drug-susceptible TB responds to the standard first-line agents. Rifampicin-resistant TB (RR-TB) has resistance to rifampicin; multidrug-resistant TB (MDR-TB) involves at least resistance to isoniazid and rifampicin. Pre-XDR-TB refers to MDR/RR-TB with additional resistance to a fluoroquinolone [4].
Resistance may be transmitted directly or arise through ineffective regimens, drug interactions, interrupted supplies or inadequate treatment. It is not proof that a patient “failed to try hard enough.” Management requires reliable susceptibility testing and specialist public-health support.
The standard six-month drug-susceptible TB regimen
For many adults and adolescents with drug-susceptible pulmonary TB, a standard regimen is two months of isoniazid, rifampicin, pyrazinamide and ethambutol (2HRZE), followed by four months of isoniazid and rifampicin (4HR)—often written 2HRZE/4HR [2,3].
| Drug | Abbreviation | Main role and safety issue |
|---|---|---|
| Isoniazid | H | Inhibits mycolic-acid synthesis; hepatotoxicity and peripheral neuropathy risks. Pyridoxine may be indicated in at-risk patients. |
| Rifampicin (rifampin) | R | Inhibits bacterial RNA polymerase; major drug interactions and orange discoloration of secretions. |
| Pyrazinamide | Z | Important sterilizing activity during the intensive phase; liver toxicity and hyperuricemia concerns. |
| Ethambutol | E | Helps protect against resistance while susceptibility is evaluated; possible optic neuropathy. |
Duration sometimes differs with cavitation and persistent culture positivity, TB meningitis, skeletal TB, drug intolerance, HIV-related considerations or other factors. This is not a self-prescribing regimen; clinicians must review susceptibility, weight, kidney/liver function and interactions.
Four-month treatment for selected drug-susceptible pulmonary TB
CDC and recent ATS/CDC/ERS/IDSA guidance support a four-month rifapentine–moxifloxacin regimen for some people with drug-susceptible pulmonary TB [3]. Its initial phase includes isoniazid (H), rifapentine (P), pyrazinamide (Z) and moxifloxacin (M), followed by isoniazid, rifapentine and moxifloxacin. It is sometimes written 2HPZM/2HPM.
CDC lists eligibility including age 12 years or older and weight at least 40 kg, with specified requirements concerning HIV treatment, interactions and drug resistance. The recommended duration is about 17 weeks, not exactly a generic four calendar months for every patient. Rifapentine-based regimens cannot be substituted freely for rifampicin-based regimens without a guideline-supported decision [3].
Shorter courses for children
The updated WHO and CDC guidance includes a four-month regimen for many children with nonsevere drug-susceptible TB, using two months of HRZE followed by two months of HR when eligible [3,4]. Severe, extrapulmonary or complex pediatric disease may require a different duration and approach.
All pediatric TB treatment requires age- and weight-appropriate dosing, a diagnosis supported by appropriate sampling and expert guidance. Adult doses should never be copied into a child.
September 2026 WHO update: drug-resistant TB
On 30 September 2026, WHO released the second edition of Module 4: Treatment and care, refining the use of shorter all-oral regimens for MDR/RR-TB and pulmonary pre-XDR-TB. A key change is selection according to severity of disease and fluoroquinolone resistance, rather than assuming one six-month regimen fits everyone [4].
| Clinical context | 2026 WHO approach | Key caveat |
|---|---|---|
| Most MDR/RR-TB | Six-month BPaLM: bedaquiline, pretomanid, linezolid and moxifloxacin. | Requires susceptibility review, eligibility and close monitoring. |
| Nonsevere pulmonary pre-XDR-TB | Six-month BPaL: bedaquiline, pretomanid and linezolid. | Fluoroquinolone resistance and disease severity must be established. |
| Severe pulmonary pre-XDR-TB | Six-month BPaLC: BPaL plus clofazimine. | Specialist selection to reduce failure or resistance amplification risk. |
| Selected patients unable to receive BPaLM | Six-month BDLLfxC: bedaquiline, delamanid, linezolid, levofloxacin and clofazimine, with regimen variants based on resistance. | Includes an alternative pathway; selection depends on severity and patient factors. |
WHO also recommends against the BDLC variant for severe pulmonary pre-XDR-TB because of concern about amplifying drug resistance, while allowing it in selected nonsevere cases. The changes reflect evolving evidence and are specialist regimens, not general combinations to prescribe without laboratory and programmatic oversight [4].
Monitoring newer drug-resistant TB regimens
All-oral shorter regimens improve convenience but have important toxicity concerns. Linezolid may cause bone-marrow suppression, peripheral/optic neuropathy and other adverse effects. Bedaquiline and some companion agents can prolong the QT interval, requiring ECG and interaction review. Pretomanid and other agents have liver and reproductive safety considerations [4].
Drug-resistant TB care requires susceptibility testing, microbiologic monitoring, symptom assessment, blood tests, ECG where relevant and pharmacovigilance. Changes should be made by a knowledgeable TB team, not through unsupervised switching based on online charts.
Tuberculosis preventive treatment
After active TB disease has been excluded, people with TB infection and a meaningful progression risk may receive preventive treatment. Common WHO/CDC options include three months of once-weekly isoniazid plus rifapentine (3HP), four months of daily rifampicin (4R) or three months of daily isoniazid plus rifampicin (3HR), depending on eligibility [5].
For people who cannot take short rifamycin regimens, six or nine months of isoniazid may be considered. Rifamycins interact with certain antiretrovirals, hormonal contraceptives, anticoagulants, anticonvulsants and other medicines, so selection must include a full drug review.
Why adherence and patient support matter
Completing TB treatment reduces relapse and limits resistance transmission. Directly observed therapy (DOT) or suitable video-supported and person-centered adherence methods may be offered within TB programs. Support with transport, nutrition, side effects, mental health, medicine supply and stigma can be as important as reminding someone to take tablets [2,4].
WHO’s September 2026 update also calls for palliative-care assessment and interventions alongside effective treatment for MDR/RR-TB to reduce suffering and improve patient-centered care. Palliative care does not mean abandoning curative therapy [4].
TB and HIV, diabetes and pregnancy
HIV coinfection requires coordination of TB treatment and antiretroviral therapy, with particular attention to rifamycin interactions, timing and immune reconstitution. Diabetes increases TB risk and can complicate response; glucose control and drug interactions deserve review [2,3].
Pregnancy changes the acceptable regimen, drug choice and monitoring needs. Untreated active TB can threaten maternal and infant health, so patients require prompt coordinated maternity/TB specialist management rather than avoiding all treatment. Pretomanid-containing regimens and other newer drugs have specific reproductive limitations and should not be copied from general adult tables [4].
Preventing TB transmission
- Identify and treat infectious cases promptly, with appropriate airborne precautions.
- Improve ventilation, respiratory protection and clinic infection control in higher-risk settings.
- Provide contact investigation and appropriate testing of exposed household members or coworkers.
- Offer preventive treatment to eligible people after active disease is excluded.
- Support BCG vaccination policies where recommended, particularly for children in high-incidence settings.
- Address overcrowding, undernutrition and barriers to accessing care.
BCG vaccination helps prevent certain severe forms of childhood TB but is not a complete shield against adult pulmonary TB. Infection control and timely treatment remain necessary.
Frequently asked questions
Does a positive IGRA mean active TB?
No. It indicates TB immune sensitization and requires clinical evaluation to exclude active disease [5].
Can TB be diagnosed from a chest X-ray alone?
No. Imaging can support suspicion, but microbiologic testing is essential whenever possible.
Does every patient need six months of TB treatment?
No. Some eligible drug-susceptible cases can receive four-month regimens, while other situations need longer or specialized treatment [3].
Is all drug-resistant TB treated for 18 months?
No. WHO’s 2026 guidance includes six-month all-oral regimens for selected MDR/RR and pre-XDR disease [4].
Is someone with latent TB infectious?
No. TB infection without active disease is not contagious.
Can TB medicines be stopped when the cough improves?
No. Premature stopping can lead to relapse or resistance; treatment should follow the prescribed regimen.
Key takeaways
TB requires accurate diagnosis, resistance testing and a complete regimen. Standard pulmonary drug-susceptible treatment often uses 2HRZE/4HR, while eligible people may use a four-month regimen. WHO’s September 2026 guidance now tailors shorter regimens for drug-resistant TB according to severity and resistance. Preventive treatment, contact tracing and patient-centered support remain central.
References
- World Health Organization. WHO updates guidelines on drug-resistant tuberculosis and palliative care. 30 Sep 2026.
- World Health Organization. Tuberculosis: overview, transmission and prevention. Accessed 8 Nov 2026.
- Centers for Disease Control and Prevention. Treatment for drug-susceptible tuberculosis disease. Updated 2025.
- World Health Organization. WHO consolidated guidelines on tuberculosis, Module 4: treatment and care. 2026 edition.
- Centers for Disease Control and Prevention. Treatment for latent tuberculosis infection. CDC.
- Centers for Disease Control and Prevention. Clinical and laboratory diagnosis for tuberculosis. CDC.
Medical disclaimer: Educational information only. TB treatment must be directed by qualified TB and public-health teams with appropriate drug-susceptibility testing, infection-control advice and safety monitoring. Serious breathing difficulty, heavy coughing of blood, confusion or signs of meningitis require urgent evaluation.
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.